Strides Arcolab, a pharmaceutical company manufacturing IP-led niche products, today announced that it has received approval from the United States Food & Drug Administration (USFDA) for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution, 420 grams/11.2 grams/5.72 grams/1.48 grams/4 litres.

According to IMS data, the US market for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution are approximately USD 20 million.

The product will be manufactured at the company's Oral dosage facility at Bangalore and marketed by Strides in the US Market.

Shares of the company gained Rs 14, or 1.16%, to trade at Rs 1,216.35. The total volume of shares traded was 20,463 at the BSE (10.23 a.m., Wednesday).